Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis

Core Insights - Kyverna Therapeutics, Inc. is set to host a conference call on October 29, 2025, to discuss interim data from the KYSA-6 Phase 2 clinical trial of KYV-101 for generalized myasthenia gravis [1] - The data will also be presented at the AANEM Annual Meeting in San Francisco from October 29 to November 1, 2025 [1] Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on cell therapies for autoimmune diseases, with its lead candidate, KYV-101, in late-stage clinical development [5] - The company is conducting registrational trials for stiff person syndrome and myasthenia gravis, along with ongoing multi-center Phase 1/2 trials for lupus nephritis [5] - Kyverna is also exploring other indications such as multiple sclerosis and rheumatoid arthritis through various trials [5] Product Details - KYV-101 is a fully human, autologous CD19 CAR T-cell therapy designed for potency and tolerability, aiming for deep B-cell depletion and immune system reset [4] - The therapy has the potential to provide durable drug-free, disease-free remission in autoimmune diseases with a single administration [4]